These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30972918)

  • 1. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.
    Wachter R; Fonseca AF; Balas B; Kap E; Engelhard J; Schlienger R; Klebs S; Wirta SB; Kostev K
    Eur J Heart Fail; 2019 May; 21(5):588-597. PubMed ID: 30972918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
    Wachter R; Viriato D; Klebs S; Grunow SS; Schindler M; Engelhard J; Proenca CC; Calado F; Schlienger R; Dworak M; Balas B; Bruce Wirta S
    Postgrad Med; 2018 Apr; 130(3):308-316. PubMed ID: 29446691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany.
    Wachter R; Klebs S; Balas B; Kap E; Engelhard J; Schlienger R; Bruce Wirta S; Fonseca AF
    ESC Heart Fail; 2020 Oct; 7(5):2318-2330. PubMed ID: 33121216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption: A STROBE-compliant study.
    Chen W; Liu Y; Tang L; Li Z; Liu Y; Dang H
    Medicine (Baltimore); 2021 Jul; 100(30):e26809. PubMed ID: 34397739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sacubitril/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study.
    Zeymer U; Groves R; Hupfer S
    Herz; 2024 Oct; 49(5):385-392. PubMed ID: 38656397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia.
    Badreldin HA; Korayem GB; Alenazy BA; Aljohani MH; Alshaya OA; Al Sulaiman K; Alabdelmuhsin L; Alenazi H; Almutairi DM; Alanazi F; Alobathani SK; Alqannam GM; Almadani O; Aljuhani O; Hafiz A; Aljowaie G; Basha E; Alqahtani T; Alhussein M
    Medicine (Baltimore); 2023 Dec; 102(51):e36699. PubMed ID: 38134075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study.
    Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
    Am J Health Syst Pharm; 2024 Jul; 81(14):599-607. PubMed ID: 38427969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M
    ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
    Luo N; Fonarow GC; Lippmann SJ; Mi X; Heidenreich PA; Yancy CW; Greiner MA; Hammill BG; Hardy NC; Turner SJ; Laskey WK; Curtis LH; Hernandez AF; Mentz RJ; O'Brien EC
    JACC Heart Fail; 2017 Apr; 5(4):305-309. PubMed ID: 28359417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience.
    Dashwood A; Vale C; Laher S; Chui F; Rheault H; Gan J; Wong YW
    Heart Lung Circ; 2020 Nov; 29(11):1688-1695. PubMed ID: 32327307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A per-protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region.
    Atallah B; Sadik ZG; Hisham M; Kalagieh O; Hamour I; Gabra G; El Banna M; Soliman M; Cherfan A; Bader F
    ESC Heart Fail; 2019 Aug; 6(4):758-763. PubMed ID: 31087629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
    Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
    Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
    Senni M; McMurray JJV; Wachter R; McIntyre HF; Anand IS; Duino V; Sarkar A; Shi V; Charney A
    Eur J Heart Fail; 2018 Mar; 20(3):491-500. PubMed ID: 29164797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.